Marina Biotech, formerly MDRNA and Nastech, is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). MDRNA, Inc. was formerly known as Nastech Pharmaceutical Company, Inc. and changed its name to MDRNA, Inc. in June 2008. The company has been building patent estates in the RNAi field, with approximately 260 filed patents addressing 144 gene sequences, including disease-validated targets. It seeks to monetize its nasal drug delivery business through licensing, partnering, or acquisition of its Phase II intranasal programs. The company was incorporated in 1983 and is headquartered in Bothell, Washington.

Acquired Companies: Cequent Pharmaceuticals, Inc.